Phoenix Bio

研究開発

研究開発

Species differences in liver accumulation and metabolism of nucleotide prodrug sofosbuvir

    Wang, T. Babusis, D. Park, Y. Niu, C. Kim, C. Zhao, X. Lu, B. Ma, B. Muench, R. C. Sperger, D. Ray, A. S. Murakami, E.

    Drug Metab Pharmacokinet. 2020 Jun;35(3):334-340. doi: 10.1016/j.dmpk.2020.04.333. Epub 2020 Apr 16.

    Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection

      Cheng, X. Uchida, T. Xia, Y. Umarova, R. Liu, C. J. Chen, P. J. Gaggar, A. Suri, V. Mucke, M. M. Vermehren, J. Zeuzem, S. Teraoka, Y. Osawa, M. Aikata, H. Tsuji, K. Mori, N. Hige, S. Karino, Y. Imamura, M. Chayama, K. Liang, T. J.

      J Clin Invest. 2020 Mar 12. pii: 135616. doi: 10.1172/JCI135616.

      Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice

        Osawa, M. Uchida, T. Imamura, M. Teraoka, Y. Fujino, H. Nakahara, T. Ono, A. Murakami, E. Kawaoka, T. Miki, D. Tsuge, M. Hiramatsu, A. Abe-Chayama, H. Hayes, C. N.

        J Gen Virol. 2019 Jul;100(7):1123-1131.

        Humanized Mouse Models for the Study of Hepatitis C and Host Interactions

          Yong, K. S. M. Her, Z. Chen, Q.

          Cells. 2019 Jun 17;8(6). pii: cells8060604.

          Combined Analysis of Metabolomes, Proteomes, and Transcriptomes of HCV-infected Cells and Liver to Identify Pathways Associated With Disease Development

            Lupberger, J. Croonenborghs, T. Roca Suarez, A. A. Van Renne, N. Juhling, F. Oudot, M. A. Virzi, A. Bandiera, S. Jamey, C. Meszaros, G. Brumaru, D. Mukherji, A. Durand, S. C. Heydmann, L. Verrier, E. R. El Saghire, H. Hamdane, N. Bartenschlager, R. Fereshetian, S. Ramberger, E. Sinha, R. Nabian, M. Everaert, C. Jovanovic, M. Mertins, P. Carr, S. A. Chayama, K. Dali-Youcef, N. Ricci, R. Bardeesy, N. M. Fujiwara, N. Gevaert, O. Zeisel, M. B. Hoshida, Y. Pochet, N. Baumert, T. F.

            Gastroenterology. 2019 Apr 9. pii: S0016-5085(19)35670-7. doi: 10.1053/j.gastro.2019.04.003.

            HCV-induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response

              Hamdane, N. Juhling, F. Crouchet, E. El Saghire, H. Thumann, C. Oudot, M. A. Bandiera, S. Saviano, A. Ponsolles, C. Roca Suarez, A. A. Li, S. Fujiwara, N. Ono, A. Davidson, I. Bardeesy, N. Schmidl, C. Bock, C. Schuster, C. Lupberger, J. Habersetzer, F. Doffoel, M. Piardi, T. Sommacale, D. mamura, M. Uchida, T. Ohdan, H. Aikata, H. Chayama, K. Boldanova, T. Pessaux, P. Fuchs, B. C. Hoshida, Y. Zeisel, M. B. Duong, F. H. T. Baumert, T. F.

              Gastroenterology. 2019 Mar 2. pii: S0016-5085(19)32506-5. doi: 10.1053/j.gastro.2019.02.038.

              Hepatic IFN-Induced Protein with Tetratricopeptide Repeats Regulation of HCV Infection

                Ishida, Y. Kakuni, M. Bang, B. R. Sugahara, G. Lau, D. T. Tateno-Mukaidani, C. Li, M. Gale, M., Jr. Saito, T.

                J Interferon Cytokine Res. 2019 Mar;39(3):133-146. doi: 10.1089/jir.2018.0103.

                Ribonucleotide reductase M2 promotes RNA replication of hepatitis C virus by protecting NS5B protein from hPLIC1-dependent proteasomal degradation

                  Kitab, B. Satoh, M. Ohmori, Y. Munakata, T. Sudoh, M. Kohara, M. Tsukiyama-Kohara, K.

                  J Biol Chem. 2019 Feb 12. pii: RA118.004397. doi: 10.1074/jbc.RA118.004397.

                  Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure

                    Teraoka, Y. Uchida, T. Imamura, M. Hiraga, N. Osawa, M. Kan, H. Saito, Y. Tsuge, M. Abe-Chayama, H. Hayes, C. N. Makokha, G. N. Aikata, H. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.

                    J Gen Virol. 2018 Jun 19. doi: 10.1099/jgv.0.001091.

                    Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice

                      Teraoka, Y. Uchida, T. Imamura, M. Osawa, M. Tsuge, M. Abe-Chayama, H. Hayes, C. N. Makokha, G. N. Aikata, H. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.

                      Biochem Biophys Res Commun. 2018 Jun 2;500(2):152-157.

                      Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection

                        Rolt, A. Le, D. Hu, Z. Wang, A. Q. Shah, P. Singleton, M. Hughes, E. Dulcey, A. E.He, S. Imamura, M. Uchida, T. Chayama, K. Xu, X. Marugan, J. J. Liang, T. J.

                        J Infect Dis. 2018 Jan 24. pii: 4823490. doi: 10.1093/infdis/jiy039.

                        A natural small molecule inhibitor corilagin blocks HCV replication and modulates oxidative stress to reduce liver damage

                          Reddy, B. U. Mullick, R. Kumar, A. Sharma, G. Bag, P. Roy, C. L. Sudha, G. Tandon, H. Dave, P. Shukla, A. Srinivasan, P. Nandhitha, M.Srinivasan, N. Das, S.

                          Antiviral Res. 2017 Dec 7;150:47-59.

                          Hepatitis C replication inhibitors that target the viral NS4B protein

                            Miller, J. F. Chong, P. Y. Shotwell, J. B. Catalano, J. G. Tai, V. W. Fang, J. Banka, A. L. Roberts, C. D. Youngman, M. Zhang, H. Xiong, Z. Mathis, A. Pouliot, J. J. Hamatake, R. K. Price, D. J. Seal, J. W., 3rd Stroup, L. L. Creech, K. L. Carballo, L. H. Todd, D. Spaltenstein, A. Furst, S. Hong, Z. Peat, A. J.

                            J Med Chem. 2014 Mar 13;57(5):2107-20

                            Evaluation of antiviral effect of type I, II, and III interferons on direct-acting antiviral-resistant hepatitis C virus

                              Hamana, A. Takahashi, Y. Uchida, T. Nishikawa, M. Imamura, M. Chayama, K. Takakura, Y.

                              Antiviral Res. 2017 Aug 31;146:130-138.

                              Critical role of CREBH-mediated induction of TGF-beta2 by HCV infection in fibrogenic responses in hepatic stellate cells

                                Chida, T. Ito, M. Nakashima, K. Kanegae, Y. Aoshima, T. Takabayashi, S. Kawata, K. Nakagawa, Y. Yamamoto, M. Shimano, H. Matsuura, T. Kobayashi, Y. Suda, T. Suzuki, T.

                                Hepatology. 2017 Jun 16. doi: 10.1002/hep.29319.

                                Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus

                                  Miyaki, E. Hiraga, N. Imamura, M. Uchida, T.  Kan, H.  Tsuge, M. Abe-Chayama, H. Hayes, C. N. Makokha, G. N. Serikawa, M. Aikata, H. Ochi, H. Ishida, Y. Tateno, C. Ohdan, H. Chayama, K.

                                  PLoS One. 2017 Mar 2;12(3):e0172412.

                                  Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology

                                    Uchida, T. Imamura, M. Kan, H. Hiraga, N. Hayes, C. N. Tsuge, M. Abe-Chayama, H. Aikata, H. Makokha, G. N. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.

                                    J Gen Virol. 2017 Jan 28. doi: 10.1099/jgv.0.000726.

                                    Protease inhibitor resistance remains even after mutant strains become undetectable using deep sequencing

                                      Kan, H. Imamura, M. Uchida, T. Hiraga, N. Hayes, C. N. Tsuge, M. Abe, H. Aikata, H. Makokha, G. N. Chowdhury, S. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.

                                      J Infect Dis. 2016 Sep 20. pii: jiw437.

                                      Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy

                                        DebRoy, S.  Hiraga, N. Imamura, M. Hayes, C. N. Akamatsu, S. Canini, L. Perelson, A. S. Pohl, R. T. Persiani, S. Uprichard, S. L. Tateno, C. Dahari, H. Chayama, K.

                                        J Viral Hepat. 2016 Jun 8. doi: 10.1111/jvh.12551.

                                        Elimination of HCV via a non-ISG-mediated mechanism by vaniprevir andBMS-788329 combination therapy in human hepatocyte chimeric mice

                                          Uchida, T. Hiraga, N. mamura, M. Yoshimi, S. Kan, H. Miyaki, E. Tsuge, M. Abe, H. Hayes, C. N. Aikata, H. Ishida, Y. Tateno, C. Ellis, J. D. Chayama, K.

                                          Virus Res. 2015 Nov 10. pii: S0168-1702(15)30117-9. doi: 10.1016/j.virusres.2015.11.010.